Stocks and Investing
Stocks and Investing
Thu, May 11, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jason Gerberry Maintained (TEVA) at Strong Buy with Decreased Target to $11 on, May 11th, 2023
Jason Gerberry of B of A Securities, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy with Decreased Target from $13 to $11 on, May 11th, 2023.
Jason has made no other calls on TEVA in the last 4 months.
There are 2 other peers that have a rating on TEVA. Out of the 2 peers that are also analyzing TEVA, 1 agrees with Jason's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Glen Santangelo of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $12 on, Thursday, January 19th, 2023
This is the rating of the analyst that currently disagrees with Jason
- Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $14 on, Thursday, February 9th, 2023
Contributing Sources